[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350262-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-350262-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","integrated-multi-omics-analysis-and-functional-validation-reveal-the-role-of-trim2-as-a-potential-novel-biomarker-in-breast-cancer","Integrated multi-omics analysis and functional validation reveal the role of TRIM2 asa potential novel biomarker in breast cancer","","Breast cancer (BRCA) remains a major health challenge due to recurrence and resistance to therapy, increasing the need for dependable biomarkers and therapeutic targets. This study integrates multi-omics resources and evaluates TRIM2, a TRIM family E3 ubiquitin ligase, using transcriptomic, proteomic, and ubiquitin-proteomic evidence. Single-cell RNA-seq characterizes TRIM2+ tumor heterogeneity and cell-cell interactions, while functional and immune profiling support TRIM2 as a tumor-suppressive prognostic biomarker linked to immune responsiveness.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-multi-omics-analysis-and-functional-validation-reveal-the-role-of-trim2-as-a-potential-novel-biomarker-in-breast-cancer/350262/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-multi-omics-analysis-and-functional-validation-reveal-the-role-of-trim2-as-a-potential-novel-biomarker-in-breast-cancer/350262.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical and therapeutic relevance did TRIM2 show?","Question",{"text":63,"@type":64},"Low TRIM2 expression correlated with advanced stage and poor overall survival, while elevated TRIM2 expression associated with improved immunotherapy responsiveness and enhanced immune checkpoint activity.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},350262,1790244715,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,97,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},"Technology",50,"technology",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},7,"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Deng et al. Breast Cancer Research (2026) 28:84 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02263-2](https://doi.org/10.1186/s13058-026-02263-2)  \nRESEARCH Open Access  \nIntegrated multi-omics analysis and functional validation reveal the role of TRIM2 asa potential novel biomarker in breast cancer  \nRumei Deng1†, Yifei Ren2†, Kaiheng Hu2†, Yanxuan Zhang2, Yihui Xu2, Qi Zhang1, Yong Li3, Xuan Huang1,4* and Feng Zhang1*  \nAbstract  \nBackground Breast cancer (BRCA) remains a major global health challenge due to its high recurrence rates and resistance to therapy, underscoring the need for reliable biomarkers and novel therapeutic targets. Tripartite motifcontaining protein 2 (TRIM2), an E3 ubiquitin ligase, has been implicated in tumorigenesis across multiple cancers, yet its role in BRCA remains poorly understood.  \nMethods We integrated multi-omics datasets from TCGA, GEO, and METABRIC, and validated TRIM2 expression using proteomic data from the Proteomic Data Commons and Human Protein Atlas. Single-cell RNA sequencing was employed to characterize the transcriptional heterogeneity and cell–cell interaction patterns ofTRIM2+ tumor cells. Ubiquitin-proteomic and proteomic profiling were conducted to identify TRIM2-regulated substrates. Drug sensitivity prediction and molecular docking were applied to assess TRIM2-related therapeutic responses, and in vitro experiments were performed to validate its biological functions.  \nResults We found that TRIM2 is consistently downregulated in BRCA tissues at both transcriptomic and proteomic levels, with low expression significantly associated with advanced stage and poor overall survival. Clinically, elevated TRIM2 expression correlated with improved responsiveness to immunotherapy. Drug sensitivity and molecular docking analyses identified 64 TRIM2-sensitive compounds, including five with strong binding affinities, suggesting potential for targeted therapeutic development. Genomic alterations and promoter hypermethylation were identified as potential mechanisms driving TRIM2 dysregulation. Multi-layered functional enrichment analyses, including transcriptomic, proteinomic, and ubiquitin-proteomic profiling, suggested that TRIM2 regulates cancer-and immune-related pathways including TGF-β, Hippo, TNF, and IL-17 signaling pathways. Single-cell RNA sequencing further demonstrated that TRIM2+ and TRIM2 − tumor cell subpopulations engage in distinct cell–cell interactions, highlighting TRIM2’s role in shaping tumor-immune communication. Functional assays confirmed that TRIM2  \n†Rumei Deng, Yifei Ren, Kaiheng Hu have contributed equally to this work.  \n*Correspondence:  \nXuan Huang [huangxuan@ncu.edu.cn](huangxuan@ncu.edu.cn)[ ](huangxuan@ncu.edu.cn)Feng Zhang [fengzhang0709@hotmail.com](fengzhang0709@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](veco","cbCaibsLtDhwF3XM","https://ap.wps.com/l/cbCaibsLtDhwF3XM","pdf",5372697,22,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background (details)","[{\"question\":\"What clinical and therapeutic relevance did TRIM2 show?\",\"answer\":\"Low TRIM2 expression correlated with advanced stage and poor overall survival, while elevated TRIM2 expression associated with improved immunotherapy responsiveness and enhanced immune checkpoint activity.\"}]","Integrated multi-omics analysis and functional validation reveal the role of TRIM2 asa potential novel biomarker in breast cancer | PDF",1790088148,55,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84a429465db1a14641aef139c4f02b1a.webp",983,1310,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c90096a1791ff4f114aa5931e373601.webp",982,1309,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20d5924dee224fd6dfb86f438ce28e50.webp",981,1308,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/004adcada89221fc82269682f0377065.webp",980,1306]